As of Dec 02
| +0.08 / +0.31%|
The 32 analysts offering 12-month price forecasts for AstraZeneca have a median target of 33.85, with a high estimate of 41.68 and a low estimate of 24.31. The median estimate represents a +30.76% increase from the last price of 25.89.
The current consensus among 35 polled investment analysts is to Buy stock in AstraZeneca. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.